Floatz logo

IBRITUMOMAB TIUXETAN

CD20+ Aggressive Non-Hodgkin's Lymphoma

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbHmonoclonal_antibodyPhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the CD20+ Aggressive Non-Hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 3BB
Eloxatin
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 2BB
LIPEGFILGRASTIM
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3BB
PEGFILGRASTIM
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3B
(+)-VINCRISTINE
Universität des Saarlandes
Phase 3B

View all 50 →

Same molecule, other indications

IBRITUMOMAB TIUXETAN is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
Lymphoma, Low-GradeDormant
BB
Indicative ·
66 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →